Patents Represented by Attorney John S. Roberts
  • Patent number: 4612315
    Abstract: Certain functionalized congeners of 1,3-dialkylxanthine exhibit high potency and selectivity as antagonists for A.sub.1 - and A.sub.2 -adenosine receptors and are suitable for attachment to probes, drug carriers, or solid supports. These derivatives are characterized by the presence of a phenyl at the 8 position para-substituted with a functionalized chain to provide high water solubility and high receptor affinity to such an extent that these compounds are suitable for use as antiallergenic, antiasthmatic, or cardiotonic drugs, central nervous system stimulants, and diuretics.
    Type: Grant
    Filed: October 26, 1984
    Date of Patent: September 16, 1986
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Kenneth A. Jacobson, John W. Daly, Kenneth L. Kirk
  • Patent number: 4612282
    Abstract: Monoclonal antibodies demonstrating a reactivity with human breast cancer are produced. The hybridoma cultures secreting immunoglobins are produced by hydridoma technology. Splenic lymphocytes of mice, immunized with membrane-enriched fractions of metastatic human mammary carcinoma tissue are fused with the NS-1 non-immunoglobulin-secreting murine myeloma cell line. Screening of immunoglobulin reactivities and double cloning of cultures yielded 11 monoclonal antibodies that demonstrated activities with the surface of human mammary tumor cells and not with the surface of apparently normal human tissues. These monoclonal antibodies aid in the diagnosis, prognosis and treatment of human breast cancer.
    Type: Grant
    Filed: March 1, 1985
    Date of Patent: September 16, 1986
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Jeffrey Schlom, David Colcher, Marianna Nuti, Patricia H. Hand, Faye Austin
  • Patent number: 4608339
    Abstract: A modified protoplast fusion method and cell line is disclosed that stably transfects human cells with pSV2-derived plasmids at frequencies greater than 10.sup.-3. This procedure makes it possible to test the biological effect of individual genes (i.e., oncogenes and other cellular genes, and viral genes). To demonstrate the utility of this invention, a pSV2gpt.sup.+ plasmid constructed to carry a subgenomic fragment of hepatitis B virus (HBV) that contained the core antigen gene (HBc gene) is transfected into human cells. Human cell lines are stably transfected with the HBC.sup.+ gene by selecting recipient cells for expression of guanine phosphoribosyl transferase expression; other selective markers, i.e., neomycin resistance, can also be used. Conditions for enhancing the expression of the transfected gene(s) have also been developed. For example, with this gpt.sup.+ /HBc.sup.
    Type: Grant
    Filed: October 25, 1983
    Date of Patent: August 26, 1986
    Inventors: George H. Yoakum, Curtis C. Harris, Brent E. Korba, John F. Lechner
  • Patent number: 4599804
    Abstract: An improved bricklayer's guide, and more particularly, a simplified and efficient adjustable support for the line used by masons as a guide for laying successive layers of bricks or blocks of various sizes. The bricklayer's guide or "line dog" consists of a combination of notched posts or standards that will cooperate in providing the desired width and a series of notches on one post that will engage an offset notch on a second post to provide the desired adjustment and secure the guide in place.
    Type: Grant
    Filed: April 24, 1984
    Date of Patent: July 15, 1986
    Inventor: Matthew P. Amos
  • Patent number: 4599308
    Abstract: An E. Coli plasmid SV40 vector recombinant is cloned to a gene of interest and amplified in bacteria. The SV40 vector-gene of interest can be introduced into eukaryotic cells by transformation or transfection and the gene of interest produces its protein product.
    Type: Grant
    Filed: September 29, 1983
    Date of Patent: July 8, 1986
    Inventors: Dean H. Hamer, Marian Kaehler, Philip Leder
  • Patent number: 4598153
    Abstract: A derivative of phencyclidine (1) bearing an isothiocyanate moiety of the meta position of the aromatic ring (2; Metaphit) has been synthesized and identified as a rapid and specific site-directed acylating agent of the [.sup.3 H]-phencyclidine binding site in rat brain homogenates.
    Type: Grant
    Filed: December 19, 1984
    Date of Patent: July 1, 1986
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Kenner C. Rice, Michael F. Rafferty, Arthur E. Jacobson, Patricia Contreras, Thomas L. O'Donohue, Ralph A. Lessor, Mariena V. Mattson
  • Patent number: 4596795
    Abstract: The administration of sex hormones, particularly testosteorne, progesterone and estradiol in the form of their complexes or inclusions with specific derivatives of cyclodextrins by the sublingual or buccal route results in effective transfer of these hormones into the systemic circulation, followed by only gradual elimination. To be effective in the above mode of administration, the derivatives of cyclodextrins must carry one or several substituents, each containing one or several hydroxy groups. Specially preferred are the following complexes: hydroxypropylbeta-cyclodextrin and poly-beta-cyclodextrin.
    Type: Grant
    Filed: April 25, 1984
    Date of Patent: June 24, 1986
    Assignee: The United States of America as represented by the Secretary, Dept. of Health & Human Services
    Inventor: Josef Pitha
  • Patent number: 4592915
    Abstract: This invention relates to the preservation of moist forage crops, high moisture grains, silages and haylages, brewer's wet and spent grains, distillers wet and spent grains and similar byproducts of fermentation used for animal feeding, and hays made from forage crops. In particular, this invention relates to the process by which these materials may be treated so as to prevent nutrient loss through excessive oxidative degradation and the concurrent heating therefrom.This invention relates to solid and emulsified compositions containing preferably 6-ethoxy-2,2,4-trimethyl-1,2-dihydroquinoline, Ethoxyquin, the addition of sorbic acid or alkali metal sorbate and optionally a mix of an alkali metal propionate and an alkaline earth metal propionate, such as calcium propionate, and an alkali metal propionate, such as sodium propionate, and method for preparation of solid and emulsified compositions embodying the above.
    Type: Grant
    Filed: May 26, 1983
    Date of Patent: June 3, 1986
    Inventors: Lewis E. Goyette, James F. Tobey, Jr.
  • Patent number: 4581231
    Abstract: A method of inactivating a lipid virus in a protein carrier by contacting said virus for an abbreviated period of time and ambient temperature with a halohydrocarbon solvent or treating agent, preferably chloroform, in an amount of 5% v/v to 50% v/v. Preferred lipid viruses are Hepatitis B virus (HBV) and non-A, non-B Hepatitis (NANBH).
    Type: Grant
    Filed: August 31, 1983
    Date of Patent: April 8, 1986
    Assignee: The United States of America as represented by the Secretary of Health and Human Services
    Inventors: Robert H. Purcell, Stephen M. Feinstone
  • Patent number: 4578355
    Abstract: A plasmid cloning vector containing both transcriptional and translational regulatory sequences derived from the bacteriophage lambda genome was constructed to achieve high level expression of prokaryotic and eukaryotic genes. The system utilizes a plasmid vehicle carrying the strong, regulatable lambda promoter, P.sub.L, and host lysogens into which this vector can be stabily transformed. The lysogen synthesizes sufficient repressor (cI) to control P.sub.L expression and thereby stabilize plasmids which carry such a highly efficient promoter. Use of a temperature sensitive repressor permits simple, rapid induction of P.sub.L transcripts at any given time. Efficient transcription of essentially any coding sequence is assured by providing the phage lambda antitermination factor, N, and a site on the transcription unit for its utilization (Nut site). This pAS1 plasmid closely resembles the earlier constructed pKC30cII, also a regulatory protein which activates promoters for lysogenic development.
    Type: Grant
    Filed: January 12, 1983
    Date of Patent: March 25, 1986
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventor: Martin Rosenberg
  • Patent number: 4573718
    Abstract: This invention is a fly-tier's combination instrument comprising a hackle plier clasp, two knot-tying tools of different diameter, a fur and hair spinning tool, and a dubbing pluck needle. These tools are combined in a telescoping instrument providing flexibility and ease of fly tying wet flies, dry flies, nymphs, streamers, and other fly tying patterns.
    Type: Grant
    Filed: June 12, 1984
    Date of Patent: March 4, 1986
    Inventor: Robert N. G. Stiver
  • Patent number: 4572896
    Abstract: A method for producing monoclonal antibody reagents against novel proteins induced by herpes simplex virus type 1 (HSV-1). The method consists of preparing HSV-1 antigen populations by infecting mammalian cells either with HSV-1 alone or with HSV-1 in the presence of an inhibitor of protein synthesis, allowing virus replication to proceed by reversing the action of said inhibitor, inoculating said antigen mixture in mice to induce the production of antibodies, fusing the spleen cells of said mice with myeloma cells to obtain hybrid cells, and screening said cells by radioimmunoprecipitation-polyacrylamide gel electrophoresis (RIP-PAGE) to identify hybrid cells producing monoclonal antibodies against HSV-1 proteins. The method teaches the production of unique monoclonal antibody reagents directed against novel HSV-1 proteins; including a 132,000 molecular weight (mw) DNA-binding protein, a 175,000 mw immediate-early protein, and a previously unknown 110,000 mw glycoprotein.
    Type: Grant
    Filed: November 22, 1982
    Date of Patent: February 25, 1986
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Berge Hampar, Martin Zweig, Stephen D. Showalter
  • Patent number: 4570397
    Abstract: A collapsible, telescoping pedestal support adapted to be extended and angularly disposed to position the topmost section thereof in a flat level plane which is comprised of a plurality of annular members nested one within the other and each including an upwardly extending tapered wall having camming means adapted to engage the next adjacent wall and lock one to the other. A plurality of pedestal supports can be utilized to provide a flat even surface to support a plurality of tiles to form a deck, floor, patio or the like.
    Type: Grant
    Filed: February 22, 1984
    Date of Patent: February 18, 1986
    Inventor: Edward J. Creske
  • Patent number: 4571385
    Abstract: This invention relates to processes which are used to produce, isolate, and characterize human rotavirus/animal rotavirus reassortants and to produce live attenuated vaccines and vaccine precursors. In the present strategy there is involved the new use of either (1) high titer hyperimmune antisera or (2) monoclonal antisera to select reassortants with the desired human phenotype. A point of novelty is the finding that antiserum or monoclonal antisera alone, so long as it possesses high titer neutralizing activity against only the 34-38Kd glycoprotein or of the animal parent, is sufficient to use for selection of reassortant rotaviruses with human phenotype. Also, the novel products are live attenuated vaccine precursors and vaccines.
    Type: Grant
    Filed: June 27, 1983
    Date of Patent: February 18, 1986
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Harry B. Greenberg, Richard G. Wyatt, Albert Z. Kapikian, Anthony R. Kalica, Karen Midthun, Robert M. Chanock
  • Patent number: 4569788
    Abstract: Monoclonal antibodies 703D4 and 704A1 detect human non-small cell lung cancer (non-SCLC) and distinguish non-SCLC from all other types of lung cancer and normal tissue cells. These two antibodies may be utilized in kit form to distinguish non-SCLC from other forms of lung cancer. These monoclonal antibodies bind to S.sup.35 methionine-incorporating protein doublets under reduced and unreduced conditions. The determinants bound by these antibodies on the 31 kiladalton protein are independent of each other as determined in radiolabelled competition assays.
    Type: Grant
    Filed: May 18, 1983
    Date of Patent: February 11, 1986
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: James L. Mulshine, John D. Minna
  • Patent number: 4569360
    Abstract: A hair curling roller adapted to be heated before being placed into the hair, consists of a hollow, cylindrical, perforated cage of a material of low heat conductivity, such as a synthetic resin, provided with a plurality of outwardly projecting teeth of the same material; and of a cylindrical sleeve of a material of high heat conductivity e.g. aluminum, inserted into the cage in intimate contact therewith. The top of the roller is preferably closed by a suitable cover or cap of a synthetic resin, either integral with the cage, or as a separate unit, while the cage and the sleeve are open at their bottom.
    Type: Grant
    Filed: November 30, 1983
    Date of Patent: February 11, 1986
    Inventor: Dov Z. Glucksman
  • Patent number: 4568673
    Abstract: A compound of the formula ##STR1## wherein Z is alkoxy of 1-4 carbon atoms or hydroxyalkoxy of 2-4 carbon atoms and Y is nitro, inhibiting the growth of murine ductal carcinoma (MXT mammary tumors).
    Type: Grant
    Filed: March 20, 1984
    Date of Patent: February 4, 1986
    Assignee: Wayne State University
    Inventors: Samuel C. Brooks, Jerome P. Horwitz
  • Patent number: 4556712
    Abstract: In a short total synthesis of morphinan compounds, derivatives of 1-benzyl-1,2,3,4-tetrahydroisoquinoline are produced. Certain of these compounds, although highly aromatic and functionalized, can be optically resolved. The optically active enantiomers can serve as important intermediates for both natural and unnatural opioids.
    Type: Grant
    Filed: March 18, 1983
    Date of Patent: December 3, 1985
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventor: Kenner C. Rice
  • Patent number: 4552758
    Abstract: A method of producing a live attenuated vaccine useful in humans which comprises producing an influenza A reassortant virus by gene exchange between an avian influenza virus parent and a human influenza virus parent and then excluding the internal genes (that code for non-surface viral proteins) of the human influenza virus parent from the reassortant by temperature selection and excluding the surface antigen genes of the avian influenza A virus parent by antibodies.
    Type: Grant
    Filed: December 20, 1983
    Date of Patent: November 12, 1985
    Assignee: St. Jude Children's Research Hospital
    Inventors: Brian R. Murphy, Robert M. Chanock, Robert G. Webster, Virginia S. Hinshaw
  • Patent number: 4552757
    Abstract: A method of producing a vaccine useful in animals which comprises producing a reassortment by gene exchange from an avian influenza A virus parent and an animal influenza A virus parent and then selecting for the reassortant containing two animal surface antigen genes and six avian internal genes by temperature and antibodies.
    Type: Grant
    Filed: December 20, 1983
    Date of Patent: November 12, 1985
    Assignee: St. Jude Children's Research Hospital
    Inventors: Brian R. Murphy, Robert M. Chanock, Robert G. Webster, Virginia S. Hinshaw